@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.ff.20240827193420.utm.medium.rss.utm.content.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.utm.source.rss-parrot-bot.v.2.18.0.post9.e462414@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
((Triple Negative Breast Neoplasmspathology[MAJR])): Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2/
Posts: 10
Followers: 2
Non-Canonical Modulation of Vitamin D Receptor Signaling by Paclitaxel in Triple-Negative Breast Cancer
Published: October 14, 2026 10:00
Triple-negative breast cancer (TNBC) is characterized by a highly aggressive phenotype and limited therapeutic options. This study investigated whether the vitamin D receptor (VDR) modulates aggressiveness and chemotherapeutic response in TNBC and explored…
Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers
Published: October 13, 2026 10:00
Triple-negative breast cancers (TNBCs) are associated with poor prognosis and chemoresistance. Recent reports indicate that extracellular matrix (ECM) molecules, such as integrins, could influence TNBC development. Integrins are adhesion macromolecules…
RecurIndex-derived molecular features associated with total pathological complete response in triple-negative breast cancer: An exploratory prospective cohort study with single-cell transcriptomic contextualization
Published: October 10, 2026 10:00
CONCLUSIONS: RecurIndex-derived molecular features were associated with tpCR in TNBC. These exploratory findings warrant validation in independent cohorts.
In Vivo Immunoscoring Technique to Monitor Anti-CD47 Immunotherapy Efficacy in Triple-Negative Breast Cancer
Published: October 9, 2026 10:00
CONCLUSION: The study documents a molecularly targeted construct for TAMs in vivo and verifies proof of the utility of using the M1/M2 ratio as a strategy for monitoring the response to CD47 treatment.
Advancements in polymer-based drug delivery systems targeting the tumor microenvironment for immunotherapy of triple-negative breast cancer
Published: October 8, 2026 10:00
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by high invasiveness, frequent recurrence, and metastasis, along with limited targeted therapeutic options. Despite clinical advances achieved with immune checkpoint…
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer
Published: October 7, 2026 10:00
CONCLUSIONS: Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy and antitumor immune response compared with olaparib. A structurally related, clinical lead compound (DSB2455) is now being tested in a phase…
Therapeutic success of sacituzumab govitecan in a patient with a primary diagnosis of triple-cancer: locally advanced triple-negative breast cancer, colon cancer and lung cancer.
Published: October 5, 2026 10:00
Triple-negative breast cancer (TNBC) remains the most aggressive form of breast cancer with a worse prognosis than other subtypes. Its high metastatic potential, limited availability of targeted therapies, and increased likelihood of being diagnosed at an…
Systemic therapy for advanced triple-negative breast cancer in older women: strategy optimization and effectiveness of sacituzumab govitecan.
Published: October 5, 2026 10:00
Triple-negative breast cancer (TNBC) represents a major challenge for clinical oncologists, due to lack of therapeutical targets deriving from hormone-receptors and/or HER2 receptor expression. Moreover, TNBC typically shows a more aggressive clinical…
Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.
Published: October 5, 2026 10:00
The clinical case described concerns a 56-years old woman with triple-negative breast cancer metastic to bone progressed with previous chemotherapy and immunotherapy. Our patient, treated in second line with sacituzumab govitecan, obtained prolonged…
Oncolytic virus encoding decorin and the CD40 ligand boosts T-cell response and achieves a durable antitumor response during breast cancer treatment
Published: October 4, 2026 10:00
Triple-negative breast cancer (TNBC) remains an aggressive disease with limited treatment options. Oncolytic adenoviruses represent a promising platform, but their efficacy as single agents is often insufficient. This study examined whether an oncolytic…